Verificando…
Traducido automáticamente. Dosis y advertencias: consulta el original en inglés. Leer en inglés

Lexovin

NAFDAC Reg. No. C4-2015 Estupefaciente

Registrado en NAFDAC. Registro activoAs of 29 October 2026 · synced automatically from official sources.
Producto
Lexovin
Número NAFDAC
C4-2015
Principio activo
Levofloxacin (Levofloxacin Hemihydrate)
Dosis
500 mg
Forma
Tablet
Tamaño del envase
1 x 10's (in Alu-Alu blister pack)
Fabricante
No Constan
Solicitante (titular)
Priya Pharmaceutical Nig Ltd
Approved
29 Sep 2022
Estado
Activo Ver en NAFDAC ↗
Registro válido hasta
28 Sep 2027
Alertas de la OMS
No se ha encontrado ninguno
Informes de la comunidad
Ninguno
Tiempos comprobados
0

Pero sobre el medicamento, Levofloxacin: uses, dosage and brands worldwide

Lo que encontramos

  • Lexovin is on the NAFDAC register with an active registration (C4-2015). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.

How to use Lexovin

Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.

Advertencia grave: SECTION WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS • Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions ( 5.1 )], including: o Tendinitis and tendon rupture [see Warnings and Precautions ( 5.2 )] o Peripheral neuropathy [see Warnings and …
Para quién es

Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated (1, 12.4). • Pneumonia: Nosocomial (1.1) and Community Acquired (1.2, 1.3) • Skin and Skin Structure Infections (SSSI): Complicated (1.4) and Uncomplicated (1.5) • Chronic bacterial prostatitis (1.6) • Inhalational Anthrax, Post-Exposure in adult and pediatric patients (1.7) • Plague in adult and pediatric patients (1.8) • Urinary Tract Infections (UTI): Complicated (1.9, 1.10) and Uncomplicated (1.12) • Acute Pyelonephritis (1.11) • Acute Bacterial Exacerbation of Chronic Bronchitis (1.13) • Acute …

Cómo tomarlo y con qué frecuencia
  • Administer Levofloxacin Tablets to pediatric patients weighing 30 kg and greater only . • Levofloxacin Tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths
  • Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg
  • Dosage in Adult and Pediatric Patients with Creatinine Clearance greater than or equal to 50 mL/minute Type of Infection Dose Every 24 hours Duration (days) Nosocomial Pneumonia 750 mg 7 to 14 Community Acquired Pneumonia 500 mg 7 to 14 Community Acquired Pneumonia 750 mg 5 Complicated SSSI 750 mg 7 to 14 Uncomplicated SSSI 500 mg 7 to 10 Chronic Bacterial Prostatitis 500 mg 28 Inhalational Anthrax (Post-Exposure)
  • Adults and Pediatric Patients 50 kg or greater
  • Pediatric Patients 30 kg to less than 50 kg 500 mg 250 mg every 12 hours 60 60 Plague
  • Adults and Pediatric Patients 50 kg or greater
  • Pediatric Patients 30 kg to less than 50 kg 500 mg 250 mg every 12 hours 10 to 14 10 to 14 Complicated UTI or Acute Pyelonephritis 750 mg 5 Complicated UTI or Acute Pyelonephritis 250 mg 10 Uncomplicated UTI 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis 500 mg 7 Acute Bacterial Sinusitis 750 mg 5 500 mg 10 to 14 • Adjust dose for creatinine clearance less than 50 mL/minute Dosage of Levofloxacin Tablets in Adult Patients with Creatinine Clearance ≥ 50 mL/minute The usual dose of …
Fortalezas en las que viene

• Levofloxacin tablets, USP 250 mg are pink colored, capsule shaped, biconvex, film coated tablets debossed with ‘25’ on one side and ‘I’ on the other side. • Levofloxacin tablets, USP 500 mg are orange colored, capsule shaped, biconvex, film coated tablets debossed with ‘26’ on one side and ‘I’ on the other side. …

Infancia
  • Quinolones, including levofloxacin, cause arthropathy and osteochondrosis in juvenile animals of several species. [see Warnings and Precautions and Animal Toxicology and/or Pharmacology ]
  • Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated
  • In pediatric patients 6 months of age and older, for inhalational anthrax (post-exposure)
  • The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate. …
Older adults

Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as levofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. …

While you are taking it
  • Advise the patient to read the FDA-approved patient labeling (Medication Guide)
  • Serious Adverse Reactions Advise patients to stop taking levofloxacin if they experience an adverse reaction and to call their healthcare provider for advice on completing the full course of treatment with another antibacterial drug
  • Inform patients of the following serious adverse reactions that have been associated with levofloxacin or other fluoroquinolone use: • Disabling and Potentially Irreversible Serious Adverse Reactions That May Occur Together: Inform patients that disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathies, and cen …
Talk to a doctor first if
  • Levofloxacin tablets are contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials [see Warnings and Precautions ]
  • Known hypersensitivity to levofloxacin or other quinolones
Medicines it may not mix with

Interacting Drug Interaction Multivalent cation-containing products including antacids, metal cations or didanosine Absorption of levofloxacin is decreased when the tablets are taken within 2 hours of these products. (2.4, 7.1) Warfarin Effect may be enhanced. Monitor prothrombin time, INR and watch for bleeding (7.2) Antidiabetic agents Carefully monitor blood glucose (5.13, 7.3) 7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and …

Warnings

Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose ( 4 , 5.7 ) Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses ( 5.6 ) Hepatotoxicity: Severe, and sometimes fatal, hepatoxicity has been reported. Discontinue immediately if signs and symptoms of hepatitis occur ( 5.8 ) Clostridium difficile -associated colitis: evaluate if diarrhea occurs ( 5.10 ) Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. …

Posibles efectos secundarios

The most common reactions (≥3%) were nausea, headache, diarrhea, insomnia, constipation and dizziness ( 6.2 ). To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Serious and Otherwise Important Adverse Reactions The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: • Disabling and Potentially Irreversible Serious Adverse Reactions [ see Warnings and Precautions (5.1)] • Tendinitis and Tendon Rupture [see Warnings and Precautions ( 5.2)] • Peripheral Neuropathy [see Warnings and Precautions (5.3)] • Central Nervous System Effect …

Pregnancy and breastfeeding

8.1 Pregnancy Pregnancy Category C. Levofloxacin was not teratogenic in rats at doses as high as 810 mg/kg/day which corresponds to 9.4 times the highest recommended oral human dose based upon relative body surface area. The oral dose of 810 mg/kg/day to rats caused decreased fetal body weight and increased fetal mortality. …

If you take too much

In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis. Levofloxacin exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of levofloxacin: ataxia, ptosis, decreased locomotor activity, dyspnea, prostration, tremors, and convulsions. Doses in excess of 1500 mg/kg orally and 250 mg/kg IV produced significant mortality in rodents.

Si olvidas una dosis

Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-03-04.

Label for levofloxacin (levofloxacin hemihydrate), the active ingredient registered with NAFDAC.

Check your pack of Lexovin

Add the expiry date on your pack for a full Trust Score.

O haz fotos de la caja
Te quedan 3 verificaciones gratis hoy Fuentes oficiales: FDA de EE. UU. · EMA (UE) · NAFDAC · alertas de la OMS

About Lexovin

What is in Lexovin?

Lexovin contains Levofloxacin (Levofloxacin Hemihydrate) (500 mg), as tablet, according to its NAFDAC registration record.

Is Lexovin registered with NAFDAC?

Yes. Lexovin is listed on the NAFDAC register under registration number C4-2015, and its registration is active as of 29 October 2026.

Has Lexovin been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Lexovin in our automatically synced alert list.

How can I check that my pack of Lexovin is genuine?

Run a free authenticity scan with the NAFDAC number C4-2015, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Lexovin?

Follow your prescription or the leaflet in your pack. The official label says: • Administer Levofloxacin Tablets to pediatric patients weighing 30 kg and greater only (2.1, 2.2). • Levofloxacin Tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg (2.2). Dosage in Adult …

What is Lexovin used for?

Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated (1, 12.4). • Pneumonia: Nosocomial (1.1) and Community Acquired (1.2, 1.3) • Skin and Skin Structure Infections (SSSI): Complicated (1.4) and Uncomplicated (1.5) • Chronic bacterial prostatitis (1.6) • I (Summarised from the official U.S. FDA label for levofloxacin (levofloxacin hemihydrate). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Lexovin? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.